Delivery Order SPE2DR25D9114-SPE2DR26FMEM7
- Not listed
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 17, 2026, for Perjeta 420 mg/14 ml vials, with a ceiling value of $58,869.72. The delivery order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract with a $499.999 billion ceiling through December 31, 2036. PPV-G GEN V authorizes DLA to issue firm fixed-price delivery orders for...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 11, 2026, for Perjeta 420 mg/14 ml vials, with a ceiling value of $44,152.29. The order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract with a $499.999 billion ceiling through December 31, 2036. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler....
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 25, 2026, for $29,434.86 to supply Perjeta 420 mg/14 ml vials. The order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award indefinite delivery contract with a $499,999,999 ceiling through December 31, 2036. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. Place of...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 2, 2026, for Perjeta 420 mg/14 ml vials with a ceiling value of $49,058.10 under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is the Defense Logistics Agency's indefinite delivery contract vehicle for pharmaceutical supply to Department of Defense healthcare facilities worldwide. The parent contract, awarded to DMS Pharmaceutical Group on November 13, 2025,...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 6, 2026, for Perjeta 420 mg/14 ml vials with a ceiling value of $4,905.81, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contract. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. The parent contract, SPE2DR, is a single-award indefinite delivery contract with a $499.999 billion ceiling and ultimate completion date of December...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 9, 2026, with a ceiling value of $14,717.43 for supply of Perjeta 420 mg/14 mL vials under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is placed under the PPV-G GEN V, a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on February 20, 2026, for $19,623.24 (ceiling value) under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contract for supply of Perjeta 420 mg/14 mL vials. The PPV-G GEN V is a Defense Logistics Agency single-award indefinite delivery contract with a $499.999 billion ceiling supporting pharmaceutical supply to Department of Defense military healthcare facilities worldwide. DMS...
- The Defense Logistics Agency issued a delivery order valued at $46,509.80 to DMS Pharmaceutical Group Inc. for Perjeta 420 mg/14 ml vials, a oncology therapeutic product. The order was awarded on December 11, 2025, with an ultimate completion date of January 5, 2026, under a firm fixed-price contract structure with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform work at its Park...
- The Defense Logistics Agency awarded a delivery order valued at $19,623.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, issued on January 14, 2026, with an ultimate completion date of February 5, 2026, carries no set-aside designation, indicating the award was made through unrestricted competition. The product will be delivered to Park...
- The Defense Logistics Agency awarded a $79,430.86 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Perjeta 420 mg/14 mL vials. The award, issued on November 13, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation and was issued without subcontractor involvement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite...
- SPE2DR25D9114Indefinite Delivery Contract
- SPE2DR25D9114-SPE2DR26FMEM7Delivery Order
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 2, 2026, for Perjeta 420 mg/14 mL vials, with a ceiling value of $49,058.10. The order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract with a $499.999 billion ceiling extending through December 31, 2036. The PPV-G GEN V program supports recurring pharmaceutical supply needs for Department of Defense military healthcare facilities worldwide. Place of performance is Park Ridge, IL 60068. The order ultimate completion date is March 23, 2026. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler. The order carries firm fixed-price pricing with no set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $49.1k | 3/1/26 |